Pathogenesis and management of acute promyelocytic leukemia

Annual Review of Medicine

Volumn 47, Issue , 1996, Pages 555-565

  Warrell Jr , Raymond P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

All trans retinoic acid; Differentiation; Retinoic acid receptors

Indexed keywords

ANTILEUKEMIC AGENT; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; BLOOD TOXICITY; CANCER CELL; CARDIOTOXICITY; CELL DIFFERENTIATION; CHROMOSOME BREAKAGE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG TOXICITY; MAINTENANCE THERAPY; METABOLIC DISORDER; NEUROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; SKIN TOXICITY;

CHROMOSOME ABERRATIONS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECEPTORS, RETINOIC ACID; REMISSION INDUCTION; TRETINOIN;

EID: 0029875959     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.47.1.555     Document Type: Review

References (44)

1. Warrell RP Jr, de Thé H, Wang Z-Y, Degos L. 1993. Acute promyelocytic leukemia. N. Engl. J. Med. 329:177-89
2. Rowley JD, Golomb HM, Dougherty C. 1977. 15/17 translocation: a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1:549-50
3. Petkovich M, Brand NJ, Krust A, Chambon P. 1987. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444-51
4. Chomienne C, Ballerini P, Balitrand N, et al. 1990. The retinoic acid receptor a gene is rearranged in retinoic-acid sensitive promyelocytic leukemia. Leukemia 4:802-7
5. Borrow J, Goddard AD, Sheer D, Solomon E. 1990. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249: 1577-80
6. de Thé H, Chomienne C, Lanotte M, et al. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 347:558-61
7. Alcalay M, Zangrilli D, Paolo P, et al. 1991. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor a locus. Proc. Natl. Acad. Sci. USA 88:1977-81
8. Lo Coco F, Avvisati G, Diverio D, et al. 1991. Molecular evaluation of response to all-trans relinoic acid therapy in patients with acute promyelocytic leukemia. Blood 77:1657-59
9. Miller WH Jr, Kakizuka A, Frankel SR, et al. 1992. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor a locus clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 89:2694-98
10. Biondi A, Rambaldi A, Pandolfi PP, et al. 1992. Molecular monitoring of the myl/ RAR-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 80:492-97
11. Castaigne S, Balitrand N, de Thé H, et al. 1992. A PML/retinoic acid receptor α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 79: 3110-15
12. Chen SJ, Chen Z, Chen A, et al. 1992. Occurrence of distinct PML/RAR α fusion gene isoforms in patients with acute promyelocytic leukemia detected by the polymerase chain reaction. Oncogene 7: 1223-32
13. Borrow J, Goddard A, Gibbons B, et al. 1992. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML/ RAR-α and RAR-α/PML fusion transcripts. Br. J.Haematol. 82:529-40
14. Lo Coco F, Diverio D, Pandolfi PP, et al. 1992. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 340: 1437-38
15. Miller WH Jr, Levine K, Diblasio A, et al. 1993. Detection of minimal residual disease in acute promyelocytic leukemia by reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 82:1689-94
16. Huang ME, Ye YC, Chen SR, et al. 1987. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia-Report of 6 cases. Chin. Med. J. 100:949-53
17. Huang ME, Ye YC, Chen SR, et al. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-72
18. Sun GL, Huang YG, Chang XF, et al. 1992. Clinial study on all-trans retinoic acid in treatment of 544 cases of acute promyelocytic leukemia treated. Chin. J. Hematol. 13:135-37
19. Castaigne S, Chomienne C, Daniel MT, et al. 1990. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. clinical results. Blood 76: 1704-9
20. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. 1991. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N. Engl. J. Med. 324: 1385-93
21. Chen ZX, Xue YQ, Zhang RI, et al. 1991. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78: 1413-19
22. Ohno R, Yoshida H, Naoe T, et al. 1992. All-trans retinoic acid (ATRA) as a differentiation therapy for refractory acute promyelocytic leukemia (APL). Proc. Am. Assoc. Cancer Res. 33:234 (Abstr.)
23. Frankel SR, Eardley A, Heller G, et al. 1994. All-trans retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann. Intern. Med. 120:278-86
24. Warrell RP Jr, Maslak P, Eardley A, 1994. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 8: 929-33
25. Fenaux P, Castaigne S, Dombret H, et al. 1992. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 80:2176-81
26. Fenaux P, Le Dely MC, Castaigne S, et al. 1993. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 82:3241-49
27. Fenaux P, Chastang C, Chomienne C, Degos L. 1994. Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia. Lancet 343:1033 (Letter)
28. Chen Z, Guidez F, Rousselot P, et al. 1994. PLZF-RARα fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc. Natl. Acad. Sci. USA 91:1178-92
29. Warrell RP Jr. 1993. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood (Editorial) 82:1949-53
30. Robertson KA, Emami B, Collins SJ. 1992. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 80: 1885-89
31. Li Y-P, Said F, Gallagher RE. 1994. Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-α. Blood 11:3298-302
32. Muindi J, Frankel S, Huselton C, et al. 1992. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 52: 2138-42
33. Lefebvre P, Thomas G, Gourmel B, et al. 1991. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 5:1054-58
34. Muindi J, Frankel SR, Miller WH Jr, et al. 1992. Continuous treatment with all-trans retinoic acid results in a progressive decrease in plasma concentrations: implications for relapse and "resistance" in acute promyelocytic leukemia. Blood 79: 299-303
35. Muindi JF, Scher HI, Rigas JR, 1994. Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans retinoic acid in patients with advanced cancer. Cancer Res. 54:2125-28
36. Cornic M, Delva L, Guidez F, et al. 1992. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res. 52: 3329-34
37. Elliott S, Taylor K, White S, et al. 1992. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 79:1916-19
38. Weis K, Rambaud S, Lavau C, et al. 1994. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 76:345-56
39. Dyck JA, Maul GG, Miller WH Jr, et al. 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333-43
40. Daniel MT, Koken M, Romagne O, et al. 1993. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82:1858-67
41. Frankel SR, Eardley A, Lauwers G, et al. 1992. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann. Intern. Med. 117:292-96
42. Vadhat L, Eardley A, Maslak P, et al. 1994. Leukocytosis, the "retinoic acid syndrome", and early mortality in patients with acute promyelocytic leukemia undergoing remission induction with all-trans retinoic acid. Blood 84:3843-19
43. 3 integrin heterodimers during retinoic acid-induced neuronal differentiation of murine embryonal carcinoma cells. J. Biol. Chem. 266:21846-52
44. Zhang Z, Tarone G, Turner DC. 1993. Expression of integrin α1β1 is regulated by nerve growth factor and dexamethasone in PC 12 cells: critical consequences for adhesion and neurite outgrowth. J. Biol. Chem. 268:5557-65